Michelle L. Basil's most recent trade in Haemonetics Corp. was a trade of 15,554 Common Stock done . Disclosure was reported to the exchange on May 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 15,554 | 49,721 (0%) | 0% | 0 | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.38 per share. | 30 May 2025 | 7,469 | 42,252 (0%) | 0% | 69.4 | 518,199 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 14,626 | 14,626 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 12,317 | 12,317 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 6,755 | 35,233 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 5,689 | 34,167 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.31 per share. | 15 May 2025 | 2,157 | 28,478 (0%) | 0% | 70.3 | 151,659 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.38 per share. | 15 May 2025 | 622 | 30,635 (0%) | 0% | 69.4 | 43,154 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2024 | 24,748 | 56,005 (0%) | 0% | 0 | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.73 per share. | 28 May 2024 | 11,758 | 44,247 (0%) | 0% | 95.7 | 1,125,593 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 87.86 per share. | 28 May 2024 | 8,896 | 35,351 (0%) | 0% | 87.9 | 781,603 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 88.57 per share. | 28 May 2024 | 4,094 | 31,257 (0%) | 0% | 88.6 | 362,606 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 9,183 | 9,183 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 4,178 | 32,861 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 95.08 per share. | 17 May 2024 | 1,604 | 31,257 (0%) | 0% | 95.1 | 152,508 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 17 May 2024 | 1,073 | 29,352 (0%) | 0% | 95 | 101,935 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.73 per share. | 17 May 2024 | 669 | 28,683 (0%) | 0% | 95.7 | 64,043 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 96.14 per share. | 15 May 2024 | 985 | 30,425 (0%) | 0% | 96.1 | 94,698 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.80 per share. | 15 May 2024 | 446 | 31,410 (0%) | 0% | 94.8 | 42,281 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.49 per share. | 15 May 2024 | 416 | 31,856 (0%) | 0% | 96.5 | 40,140 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 89.05 per share. | 20 Oct 2023 | 197 | 32,272 (0%) | 0% | 89.1 | 17,543 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 18 May 2023 | 3,541 | 32,469 (0%) | 0% | 83.3 | 295,107 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 9,502 | 9,502 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 4,205 | 36,456 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 89.21 per share. | 15 May 2023 | 446 | 36,010 (0%) | 0% | 89.2 | 39,788 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.16 per share. | 12 May 2023 | 204 | 32,251 (0%) | 0% | 88.2 | 17,985 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 80.39 per share. | 24 Oct 2022 | 180 | 32,455 (0%) | 0% | 80.4 | 14,470 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 78.36 per share. | 19 Sep 2022 | 11,448 | 32,635 (0%) | 0% | 78.4 | 897,065 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.64 per share. | 19 Sep 2022 | 4,213 | 43,072 (0%) | 0% | 41.6 | 175,429 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2022 | 4,213 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.43 per share. | 19 Sep 2022 | 3,464 | 38,859 (0%) | 0% | 38.4 | 133,122 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2022 | 3,464 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.57 per share. | 19 Sep 2022 | 1,011 | 44,083 (0%) | 0% | 56.6 | 57,192 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Sep 2022 | 1,011 | 12,553 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 77.76 per share. | 15 Sep 2022 | 27,769 | 41,424 (0%) | 0% | 77.8 | 2,159,317 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.64 per share. | 15 Sep 2022 | 14,231 | 66,020 (0%) | 0% | 41.6 | 592,579 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 14,231 | 4,213 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 11,154 | 3,464 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.43 per share. | 15 Sep 2022 | 11,154 | 51,789 (0%) | 0% | 38.4 | 428,648 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 78.50 per share. | 15 Sep 2022 | 6,029 | 35,395 (0%) | 0% | 78.5 | 473,277 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 3,173 | 13,564 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.57 per share. | 15 Sep 2022 | 3,173 | 69,193 (0%) | 0% | 56.6 | 179,497 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 62.60 per share. | 13 Jun 2022 | 277 | 40,635 (0%) | 0% | 62.6 | 17,340 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 59.10 per share. | 19 May 2022 | 3,258 | 40,912 (0%) | 0% | 59.1 | 192,548 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 14,208 | 14,208 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 6,076 | 44,170 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 56.10 per share. | 16 May 2022 | 196 | 38,094 (0%) | 0% | 56.1 | 10,996 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 71.93 per share. | 25 Oct 2021 | 120 | 38,290 (0%) | 0% | 71.9 | 8,632 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 59.87 per share. | 14 Jun 2021 | 195 | 38,410 (0%) | 0% | 59.9 | 11,675 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 55.09 per share. | 07 Jun 2021 | 442 | 38,605 (0%) | 0% | 55.1 | 24,350 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 17,677 | 39,267 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 16,737 | 16,737 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 6,187 | 21,590 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 55.19 per share. | 18 May 2021 | 220 | 39,047 (0%) | 0% | 55.2 | 12,142 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 55.97 per share. | 17 May 2021 | 204 | 15,403 (0%) | 0% | 56.0 | 11,418 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 120.07 per share. | 08 Mar 2021 | 385 | 15,607 (0%) | 0% | 120.1 | 46,227 | Common Stock |
| Haemonetics Corp. | Michelle L. Basil | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 106.58 per share. | 23 Oct 2020 | 181 | 15,992 (0%) | 0% | 106.6 | 19,291 | Common Stock |